New York State Teachers Retirement System continued to hold its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,086 shares of the medical instruments supplier’s stock at the end of the first quarter. New York State Teachers Retirement System’s holdings in AngioDynamics were worth $262,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Fenimore Asset Management Inc. bought a new position in shares of AngioDynamics during the first quarter worth about $9,214,000. Norges Bank acquired a new stake in AngioDynamics during the fourth quarter valued at approximately $2,699,000. State Street Corp increased its stake in AngioDynamics by 21.4% in the fourth quarter. State Street Corp now owns 801,613 shares of the medical instruments supplier’s stock valued at $13,518,000 after buying an additional 141,424 shares during the period. Royce & Associates LP increased its stake in AngioDynamics by 18.7% in the first quarter. Royce & Associates LP now owns 810,312 shares of the medical instruments supplier’s stock valued at $14,059,000 after buying an additional 127,764 shares during the period. Finally, American Century Companies Inc. increased its stake in AngioDynamics by 65.9% in the first quarter. American Century Companies Inc. now owns 297,659 shares of the medical instruments supplier’s stock valued at $5,164,000 after buying an additional 118,250 shares during the period. Institutional investors and hedge funds own 89.19% of the company’s stock.
Shares of AngioDynamics, Inc. (NASDAQ:ANGO) traded up 0.343% during mid-day trading on Thursday, reaching $16.958. 109,025 shares of the company were exchanged. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.18. The stock has a 50 day moving average price of $16.25 and a 200-day moving average price of $16.17. The stock has a market capitalization of $620.32 million, a P/E ratio of 123.781 and a beta of 1.15.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 18th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.03. The company had revenue of $86.90 million for the quarter, compared to analysts’ expectations of $90.72 million. AngioDynamics had a net margin of 2.00% and a return on equity of 5.19%. AngioDynamics’s revenue was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.19 EPS. Analysts predict that AngioDynamics, Inc. will post $0.67 earnings per share for the current year.
Several analysts have recently commented on ANGO shares. Canaccord Genuity reaffirmed a “hold” rating and issued a $16.50 price objective on shares of AngioDynamics in a report on Wednesday, May 31st. Cantor Fitzgerald upped their price objective on shares of AngioDynamics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Tuesday, July 4th. Barclays PLC dropped their price objective on shares of AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 19th. Zacks Investment Research downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Thursday, July 20th. Finally, BidaskClub downgraded shares of AngioDynamics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $18.50.
In related news, CEO James C. Clemmer bought 5,000 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,368,724.57. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO James C. Clemmer bought 20,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were bought at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,355,722.12. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,316 shares of company stock worth $396,806 over the last 90 days. Insiders own 1.88% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
